\u4e2d\u56fd\u5317\u4eac<\/span>2022\u5e744\u670815\u65e5<\/span> \/\u7f8e\u901a\u793e\/ — \u751f\u7269\u533b\u836f\u9ad8\u79d1\u6280\u516c\u53f8\u8bfa\u8bda\u5065\u534e\uff08\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a09969\uff09\u4eca\u5929\u5ba3\u5e03\uff0c\u516c\u53f8\u5c06\u57282022\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e00\u7cfb\u5217\u5728\u7814\u7ba1\u7ebf\u6700\u65b0\u6570\u636e\u3002<\/p>\n 2022\u5e74ASCO\u5e74\u4f1a\u5c06\u4e8e2022\u5e746\u67083\u65e5\u52307\u65e5\u5728\u829d\u52a0\u54e5\u4ee5\u7ebf\u4e0a\u7ebf\u4e0b\u5f62\u5f0f\u4e3e\u529e\u3002ASCO \u5e74\u4f1a\u662f\u5168\u7403\u80bf\u7624\u9886\u57df\u6743\u5a01\u7684\u5b66\u672f\u4ea4\u6d41\u76db\u4f1a\uff0c\u5c06\u5c55\u793a\u5f53\u524d\u56fd\u9645\u524d\u6cbf\u7684\u4e34\u5e8a\u80bf\u7624\u5b66\u79d1\u7814\u6210\u679c\u548c\u80bf\u7624\u6cbb\u7597\u6280\u672f\u3002<\/p>\n \u58c1\u62a5\u5c55\u793a<\/b>1: <\/b><\/p>\n \u6807\u9898\uff1a\u9ad8\u9009\u62e9\u6027\u7684\u4e0d\u53ef\u9006 FGFR 1-4 \u6291\u5236\u5242gunagratinib (ICP-192)\u6cbb\u7597FGF\/FGFR \u57fa\u56e0\u6539\u53d8\u7684\u5934\u9888\u764c\u60a3\u8005\u7684\u4e34\u5e8aI\u671f\u6570\u636e <\/p>\n Title: Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer harboring FGF\/FGFR gene aberrations<\/p>\n \u6458\u8981\u4ee3\u7801\uff1a6039<\/p>\n \u5206\u4f1a\u573a\uff1a \u5934\u9888\u764c<\/p>\n \u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff1a2022\u5e746\u67086\u65e5\uff08\u661f\u671f\u4e00\uff09\u4e0b\u53481:15-4:15<\/p>\n \u62a5\u544a\u4eba\uff1a\u90ed\u6654\u6559\u6388<\/p>\n \u58c1\u62a5\u5c55\u793a<\/b>2: <\/b><\/p>\n \u6807\u9898\uff1a\u9ad8\u9009\u62e9\u6027\u7684\u65b0\u578b\u6cdbTRK\u6291\u5236\u5242ICP-723\u5728\u5b9e\u4f53\u7624\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\uff08PK\uff09\u7279\u6027\u548c\u4e34\u5e8a\u7597\u6548<\/p>\n Title: Safety, pharmacokinetics (PK) and clinical efficacy of ICP-723, a highly selective next-generation pan-TRK inhibitor, in patients with solid tumor<\/p>\n \u6458\u8981\u4ee3\u7801\uff1a3106<\/p>\n \u5206\u4f1a\u573a\uff1a\u5f00\u53d1\u4e2d\u7684\u7597\u6cd5 — \u5206\u5b50\u9776\u5411\u836f\u4e0e\u80bf\u7624\u751f\u7269\u5b66<\/p>\n \u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff1a2022\u5e746\u67085\u65e5\uff08\u661f\u671f\u65e5\uff09\u4e0a\u53488:00-11:00<\/p>\n \u62a5\u544a\u4eba\uff1a\u9b4f\u5c0f\u4e3d\u535a\u58eb<\/p>\n \u5728\u7ebf\u53d1\u5e03<\/b>: <\/b><\/p>\n \u6807\u9898\uff1a\u5965\u5e03\u66ff\u5c3c\u6cbb\u7597\u5f25\u6f2b\u6027\u5927B\u7ec6\u80de\u6dcb\u5df4\u7624\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\uff1a\u771f\u5b9e\u4e16\u754c\u6570\u636e\u5206\u6790<\/p>\n Title: Efficacy and safety of orelabrutinib in diffuse large B-cell lymphoma: a real-world analysis<\/p>\n \u6458\u8981\u4ee3\u7801\uff1ae19556<\/p>\n \u7f8e\u56fd\u4e1c\u90e8\u53d1\u5e03\u65f6\u95f4\uff1a2022\u5e745\u670826\u65e5\uff08\u661f\u671f\u56db\uff09\u4e0b\u53485:00<\/p>\n \u7b2c\u4e00\u4f5c\u8005\uff1a\u8bb8\u5f6d\u9e4f\u6559\u6388<\/p>\n \u901a\u8baf\u4f5c\u8005\uff1a\u8d75\u7ef4\u8385\u6559\u6388<\/p>\n \u5173\u4e8e\u8bfa\u8bda\u5065\u534e<\/b><\/p>\n \u8bfa\u8bda\u5065\u534e\uff08\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a09969\uff09\u662f\u4e00\u5bb6\u5546\u4e1a\u5316\u9636\u6bb5\u7684\u751f\u7269\u533b\u836f\u9ad8\u79d1\u6280\u516c\u53f8\uff0c\u4e13\u6ce8\u4e8e\u6076\u6027\u80bf\u7624\u53ca\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u6cbb\u7597\u9886\u57df\u7684\u4e00\u7c7b\u65b0\u836f\u7814\u5236\uff0c\u9002\u7528\u4e8e\u6cbb\u7597\u6dcb\u5df4\u7624\u3001\u5b9e\u4f53\u7624\u548c\u81ea\u8eab\u514d\u75ab\u6027\u75be\u75c5\u3002\u73b0\u6709\u591a\u4e2a\u65b0\u836f\u4ea7\u54c1\u5904\u4e8e\u5546\u4e1a\u5316\u3001\u4e34\u5e8a\u53ca\u4e34\u5e8a\u524d\u7814\u53d1\u9636\u6bb5\u3002\u516c\u53f8\u5728\u5317\u4eac\u3001\u5357\u4eac\u3001\u4e0a\u6d77\u3001\u5e7f\u5dde\u3001\u9999\u6e2f\u3001\u7f8e\u56fd\u65b0\u6cfd\u897f\u548c\u6ce2\u58eb\u987f\u5747\u8bbe\u6709\u5206\u652f\u673a\u6784\u3002<\/p>\n \u76f8\u5173\u94fe\u63a5\uff1ahttps:\/\/cn.innocarepharma.com\/cn\/<\/a><\/span><\/p>\n \u8054\u7cfb\u4eba<\/b><\/p>\n \u5a92\u4f53<\/b> \u6295\u8d44\u8005 \u4e2d\u56fd\u5317\u4eac2022\u5e744\u670815\u65e5 \/\u7f8e\u901a\u793e\/ — \u751f\u7269\u533b\u836f\u9ad8\u79d1\u6280\u516c\u53f8\u8bfa\u8bda\u5065\u534e\uff08\u9999\u6e2f\u8054\u4ea4\u6240\u4ee3\u7801\uff1a09969\uff09\u4eca\u5929\u5ba3\u5e03\uff0c\u516c\u53f8\u5c06\u57282022\u5e74\u7f8e\u56fd\u4e34\u5e8a\u80bf\u7624\u5b66\u4f1a\uff08ASCO\uff09\u5e74\u4f1a\u4e0a\u516c\u5e03\u4e00\u7cfb\u5217\u5728\u7814\u7ba1\u7ebf\u6700\u65b0\u6570\u636e\u3002 2022\u5e74ASCO\u5e74\u4f1a\u5c06\u4e8e2022\u5e746\u67083\u65e5\u52307\u65e5\u5728\u829d\u52a0\u54e5\u4ee5\u7ebf\u4e0a\u7ebf\u4e0b\u5f62\u5f0f\u4e3e\u529e\u3002ASCO \u5e74\u4f1a\u662f\u5168\u7403\u80bf\u7624\u9886\u57df\u6743\u5a01\u7684\u5b66\u672f\u4ea4\u6d41\u76db\u4f1a\uff0c\u5c06\u5c55\u793a\u5f53\u524d\u56fd\u9645\u524d\u6cbf\u7684\u4e34\u5e8a\u80bf\u7624\u5b66\u79d1\u7814\u6210\u679c\u548c\u80bf\u7624\u6cbb\u7597\u6280\u672f\u3002 \u58c1\u62a5\u5c55\u793a1: \u6807\u9898\uff1a\u9ad8\u9009\u62e9\u6027\u7684\u4e0d\u53ef\u9006 FGFR 1-4 \u6291\u5236\u5242gunagratinib (ICP-192)\u6cbb\u7597FGF\/FGFR \u57fa\u56e0\u6539\u53d8\u7684\u5934\u9888\u764c\u60a3\u8005\u7684\u4e34\u5e8aI\u671f\u6570\u636e Title: Phase I results of gunagratinib (ICP-192), a highly selective irreversible FGFR 1-4 inhibitor in patients with head and neck cancer harboring FGF\/FGFR gene aberrations \u6458\u8981\u4ee3\u7801\uff1a6039 \u5206\u4f1a\u573a\uff1a \u5934\u9888\u764c \u7f8e\u56fd\u4e2d\u90e8\u65f6\u95f4\uff1a2022\u5e746\u67086\u65e5\uff08\u661f\u671f\u4e00\uff09\u4e0b\u53481:15-4:15 \u62a5\u544a\u4eba\uff1a\u90ed\u6654\u6559\u6388 \u58c1\u62a5\u5c55\u793a2: \u6807\u9898\uff1a\u9ad8\u9009\u62e9\u6027\u7684\u65b0\u578b\u6cdbTRK\u6291\u5236\u5242ICP-723\u5728\u5b9e\u4f53\u7624\u60a3\u8005\u4e2d\u7684\u5b89\u5168\u6027\u3001\u836f\u4ee3\u52a8\u529b\u5b66\uff08PK\uff09\u7279\u6027\u548c\u4e34\u5e8a\u7597\u6548 Title: Safety, pharmacokinetics (PK) and clinical efficacy of ICP-723, a highly selective… Read More<\/a><\/p>\n","protected":false},"author":556,"featured_media":8278,"comment_status":"close","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1965],"tags":[],"class_list":["post-67746","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-partnerships"],"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/67746","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/users\/556"}],"replies":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/comments?post=67746"}],"version-history":[{"count":1,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/67746\/revisions"}],"predecessor-version":[{"id":67747,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/posts\/67746\/revisions\/67747"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media\/8278"}],"wp:attachment":[{"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/media?parent=67746"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/categories?post=67746"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.xinwengao.com\/cn\/wp-json\/wp\/v2\/tags?post=67746"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\u9646\u6625\u534e
86-10-66609879
chunhua.lu@innocarepharma.com<\/a> <\/p>\n
<\/b>86-10-66609999
ir@innocarepharma.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"